排名前五的药物类型 | 数量 |
---|---|
小分子化药 | 5 |
排名前五的靶点 | 数量 |
---|---|
PGI2 receptor(前列腺素IP受体) | 2 |
AXL x VEGFR2 x c-Met | 1 |
靶点- |
作用机制- |
原研机构 |
在研适应症 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
开始日期2025-04-07 |
申办/合作机构 |
开始日期2025-04-07 |
申办/合作机构 |
开始日期2025-03-24 |
申办/合作机构 |
Fruiting bodies of mushrooms represent an important functional food owing to various beneficial health enhancing effects. The edible mushroom Pholiota limonella (Strophariaceae, Agaricomycetes) has been found to contain various bioactive components. In this study, the proximate amino and fatty acids, as well as volatile compounds of P. limonella were analyzed to assess its nutritional and aromatic profiles. The in vitro antioxidant activity of P. limonella extract was evaluated using DPPH, ABTS, and hydroxyl radical-scavenging assays. The results showed that P. limonella possesses antioxidant activity and provided a good research basis for the comprehensive development of P. limonella as functional food product.
药物(靶点) | 适应症 | 全球最高研发状态 |
---|---|---|
SYN045 | 肺动脉高压 更多 | 临床1期 |
NP-01(Shijiazhuang No. 4 Pharmaceutical Co., Ltd.) ( AXL x VEGFR2 x c-Met ) | 晚期恶性实体瘤 更多 | 临床1期 |
ADN-9 | 肝硬化 更多 | 临床前 |
CN118598820 ( PGI2 receptor )专利挖掘 | 坏疽 更多 | 药物发现 |
CN118619893 ( PGI2 receptor )专利挖掘 | 肺动脉高压 更多 | 药物发现 |